Aarey Drugs & Pharma Publishes Q3 FY26 Unaudited Financial Results
Aarey Drugs & Pharmaceuticals Limited announced its unaudited financial results for Q3 FY26. Total income from operations for the quarter was ₹274.66 Lakhs, with a net profit before tax of ₹230.23 Lakhs. For the nine months ended December 31, 2025, total income was ₹(331.75) Lakhs and net profit before tax was ₹(452.10) Lakhs.
The announcement is a routine disclosure of financial results and does not contain any significant new information or strategic changes that would materially impact the company's stock or operations.
The financial results show a profit for the quarter but a loss for the nine-month period, indicating mixed performance. The announcement is primarily a disclosure of results.
Aarey Drugs & Pharmaceuticals Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The results were approved by the Board of Directors at a meeting held on February 11, 2026.
The company reported its financial results in a newspaper advertisement published in ‘Active Times’ on February 13, 2026, and in ‘Mumbai Lakshadeep’ on February 14, 2026. These results have also been uploaded to the company's website.
For the quarter ended December 31, 2025, Aarey Drugs & Pharmaceuticals Limited reported a Total Income from Operations of ₹274.66 Lakhs and a Net Profit for the period (before tax) of ₹230.23 Lakhs. For the nine months ended December 31, 2025, the Total Income from Operations was ₹(331.75) Lakhs and the Net Profit for the period (before tax) was ₹(452.10) Lakhs. The paid-up equity share capital stood at ₹20.02 Lakhs.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.